Michael J Kittay Md Pc Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 23 Middle Street, Suite 2, Newburyport, RI 01950 Phone: 978-449-0019 |
News Archive
At the request of the U.S. Food and Drug Administration, U.S. Marshals on March 31 seized a range of consumer products, including creams, capsules, tablets, gum, throat spray, and shampoos from a Haywood, Wis., manufacturer.
Stimulation of a receptor in the brain that controls insulin responses has been shown to halt or diminish the neurodegeneration of Alzheimer's disease, providing evidence that the disease can be treated in its early stages, according to a study by researchers at Rhode Island Hospital and Brown Medical School.
Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.
Raptor Pharmaceuticals Corp. has announced positive results in its Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.
American CareSource Holdings, Inc., the nation's leading ancillary health care network services company, announced today that it has signed and implemented an agreement with Annapolis, Maryland-based Self Funding Administrators Corporation, a third party administrator representing an additional 30,000 covered lives.
› Verified 5 days ago